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Abstract Selective agonists of peroxisome proliferator-
activated receptor gamma (PPARc) are anti-diabetic
drugs that enhance cellular responsiveness to insulin.
However, in some patients, fluid retention, plasma vol-
ume expansion, and edema have been observed. It is well
established that insulin regulates Na+ reabsorption via
the epithelial sodium channel (ENaC) located in the
distal tubule. Therefore, we hypothesized that these ag-
onists may positively modulate insulin-stimulated ENaC
activity leading to increased Na+ reabsorption and fluid
retention. Using electrophysiological techniques, dose–
response curves for insulin-mediated Na+ transport in
the A6, M-1, and mpkCCDcl4 cell lines were performed.
Each line demonstrated hormone efficacy within physi-
ological concentration ranges and, therefore, can be
used to monitor clinically relevant effects of pharmaco-
logical agents which may affect electrolyte transport.
Immunodetection and quantitative PCR analyses
showed that each cell line expresses viable and func-
tional PPARc receptors. Despite this finding, two
PPARc agonists, pioglitazone and GW7845 did not di-
rectly enhance basal or insulin-stimulated Na+ flux via
ENaC, as shown by electrophysiological methodologies.
These studies provide important results, which eliminate
insulin-mediated ENaC activation as a candidate
mechanism underlying the fluid retention observed with
PPARc agonist use.
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Introduction
There is an ever-increasing need for well-defined in vitro
model systems which can be used to investigate intra-
cellular signaling mechanisms within specific cell types of
organ systems. The kidney exemplifies a complex organ
in which the epithelial cells lining the tubules show
segment-specific differences in transepithelial resistance
and permeability as well as expression of distinct hor-
mone receptors and transport proteins.
Cultured cell models expressing the in vivo charac-
teristics of various tubular segments have been devel-
oped and serve as valuable models for studies that would
not be possible in the context of the variability present in
the whole organ. In the cortical collecting duct, the
principal cells are responsive to three different hor-
mones: aldosterone, antidiuretic hormone (ADH), and
insulin/IGF1 (insulin-like growth factor 1). Each of
these hormones positively regulates the epithelial Na+
channel (ENaC), and, therefore, plays a crucial role in
overall salt and water homeostasis.
While the pharmacology of the aldosterone response
is relatively well defined in the available principal cell
culture models, the responses to insulin are less well
characterized. There is an emerging appreciation for the
potential role of insulin in the development of hyper-
tension in hyperinsulinemic states, thereby underscoring
the need for well-characterized cell lines that can be used
to model these clinical observations. Such cultured lines
can also be utilized to investigate the efficacy and
mechanism of action of pharmaceutical agents that
target insulin-stimulated pathways.
Peroxisome proliferator-activated receptor gamma
(PPARc) is a nuclear transcription factor that, when
activated, plays a functional role in free fatty acid
metabolism and adipocyte differentiation [35]. The
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thiazolidinedione (TZD) class of therapeutic compounds
are high-affinity ligands for PPARc [22], which have
been shown to enhance cellular responsiveness to insu-
lin, increase insulin-dependent glucose disposal, and
improve hepatic sensitivity to insulin with overall
durable improvement in glucose homeostasis. There are
two FDA-approved TZDs—rosiglitazone (Avandia)
and pioglitazone (Actos)—used in the treatment of type
2 diabetes mellitus (T2DM) either alone or in combi-
nation with metformin, sulfonylureas or insulin.
When used as monotherapy, there are reports of
TZDs causing fluid retention that can result in plasma
volume expansion and, in some patients, overt edema.
The incidence of edema is increased when either of these
agents is used in combination with insulin [27]. How-
ever, the mechanisms involved in the fluid retentive ef-
fects have not been well described. Interestingly, while
the agents cause fluid retention, they also exhibit blood
pressure lowering activity in normotensive and hyper-
tensive rodents and humans [5, 6, 21, 32].
One potential target tissue for the fluid retentive
action of these ligand-activated transcription factors is
the vasculature. PPARc is expressed in endothelial and
smooth muscle cells [7, 21] and receptor activation
appears to have direct vasodilatory effects in humans
and rodents [5, 15, 28]. Even with changes in the vas-
culature, the observed clinical symptoms of salt and
water retention suggest a primary or secondary effect
on renal salt and water homeostasis. Localization of
PPARc in the glomerular mesangial cells [16, 18, 20]
and the distal portions of the nephron [16, 19, 36]
suggest a potential for direct effects of PPARc agonists
on renal function.
The current studies were designed to characterize the
dose–response relationships for insulin-stimulated Na+
transport in several principal cell culture models
including the A6 (derived from Xenopus laevis) [3] and
murine M-1 [33] and mouse principal kidney cortical
collecting duct (mpkCCDcl4) [2] cell lines. Subsequently,
the cell lines were used to examine the potential renal
involvement of PPARc agonist-induced edema forma-
tion and to determine whether insulin’s exacerbation of
this effect could be manifested via Na+ retention.
Materials and methods
Drugs and cell lines
The A6 and M-1 cell lines were obtained from ATCC
(Rockville, MD, USA). The mpkCCDcl4 cell line was
provided by Dr. Alain Vandewalle (INSERM U478,
Paris, France). Porcine insulin was obtained from Eli
Lilly Corporation (Indianapolis, IN, USA). Amiloride
was purchased from Sigma Chemical Co. (St. Louis,
MO, USA). Pioglitazone and GW7845 were provided
by GlaxoSmithKline (Research Triangle Park, NC,
USA).
Cell culture
The A6 cell line was grown at 27C in a humidified
incubator gassed with 4.5% CO2. Culture media con-
sisted of seven parts Coon’s F12 High Zinc and three
parts Leibovitz’s L15 (Irvine Scientific; Santa Ana, CA,
USA), supplemented with 10% calf serum (ICN Bio-
chemicals Inc., Irvine, CA, USA), 25 mM NaHCO3,
25 U/ml penicillin, 25 mg/ml streptomycin, 1 mM
Glutamax (Invitrogen; Carlsbad, CA, USA), and 12 mg/
l ciprofloxacin (Voigt Global Distribution; Kansas City,
MO, USA). The mammalian cell lines (M-1 and
mpkCCDcl4) were grown at 37C in a humidified incu-
bator gassed with 5% CO2. Culture media consisted of
DMEM/F12 base media (Invitrogen) supplemented with
5% fetal bovine serum (ICN Biochemicals Inc.), 1 mM
Glutamax, 25 U/ml penicillin, 25 mg/ml streptomycin,
and 12 mg/l ciprofloxacin. For all cell lines, media was
replaced every 2 days. Cell cultures were maintained in
plastic flasks until confluent and subcultured at a 1 : 10
dilution. For electrophysiological experiments, cells
were subcultured onto permeable supports (Costar
Transwells; Fisher, Chicago, IL, USA) at confluent
density. All cells were grown on permeable supports for
at least 14 days prior to electrophysiological studies.
Electrophysiology
Transwell filters containing confluent cell monolayers
were clamped in a Ussing chamber and connected to a
voltage clamp apparatus (WPI; Sarasota, FL, USA) via
current and voltage electrodes. The initial transepithe-
lial voltage was clamped to zero and the resulting
short-circuit current (SCC) measured. The cells were
bathed with the appropriate serum-free media, which
was maintained at either 27 or 37C for the A6 cell line
and mammalian cell lines, respectively. A 5/95% CO2/
O2 gas lift served to circulate the bathing media, as well
as maintain pH. All cell lines were serum-starved for
18–24 h prior to electrophysiological studies. Either
pioglitazone (10 lM) or GW7845 (100 nM) was added
to the serosal bathing media 18–24 h prior to and
during electrophysiological studies. In all experiments,
insulin was added to the serosal bathing media and
amiloride (105 M) was added to the apical bathing
media 30 min after insulin addition. Transepithelial
resistance (an indication of cellular viability) was
monitored throughout the entire duration of each
electrophysiological experiment by pulsing the tissues
with a 2,000 lV pulse every 200 s. Resistance values
were calculated from the resulting current deflections
using Ohm’s law. By convention, an increase in SCC is
indicative of cation absorption (apical to basal flux) or
of anion secretion (basal to apical flux). A6 and
mpkCCDcl4 cells were only used in statistical analyses if
tissue resistances were ‡1,000 XÆcm2 . M-1 cells were
only included in statistical analyses if tissue resistances
were ‡500 XÆcm2 .
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Total RNA extraction, reverse transcription,
and quantitative polymerase-chain reaction
Total RNA from untreated M-1 and mpkCCDcl4 cells
grown on plastic (for PPARc gene expression analyses)
or from PPARc-treated mpkCCDcl4 cells grown on
semi-permeable supports (for CD36 and SGK gene
expression analyses) were extracted using RNeasy mini
column (Qiagen; Valencia, CA, USA) and digested
with DNase (Qiagen) following the manufacturer’s
instructions to remove DNA contamination. One
microgram of cleaned total RNA was reverse tran-
scribed in 100 ll reaction using the High Capacity
cDNA Archive Kit (Applied Biosystems; Foster City,
CA, USA). Quantitative polymerase-chain reaction
(qPCR) was performed and analyzed using ABI
PRISM 7000 Sequence Detection System (Applied
Biosystems) with gene-specific primers and probes.
Mouse-specific oligonucleotides used in qPCR analyses
are outlined in Table 1.
Gel electrophoresis and western blotting
Cells grown on permeable supports were washed in ice-
cold serum-free culture media and solubilized with lysis
buffer (4% SDS, 10% glycerol, and 1 mM DTT in
0.05 M Tris, pH 6.8). Lysates were sonicated for 20 1-s
pulses with a titanium-tip sonicator (20% duty cycle,
Branson Sonifier 450). Protein concentration was
determined using the DC protein assay kit (Biorad;
Hercules, CA, USA). The cell lysates were separated by
SDS-PAGE on 7.5% acrylamide gels and blotted onto
Immobilon-P transfer membrane (Millipore Corp.;
Bedford, MA, USA). The membranes were blocked with
5% milk-TBS, pH 7.5 and subsequently incubated
overnight at 4C with gentle agitation with either an
anti-PPARc antibody (Affinity BioReagents; Golden,
CO) at a 1:3,000 dilution, an anti-CD36 antibody
(Cayman Chemical; Ann Arbor, MI) at a 1:1,000 dilu-
tion, or an anti-SGK antibody (Dr. Nicola Perrotti;
Univ. Magna Graecia of Catanzaro, Catanzaro, Italy) at
a 1:1,000 dilution followed by incubation with anti-
rabbit antibody conjugated to horseradish peroxidase
(Upstate Inc.; Charlottesville, VA, USA) at a 1:10,000 or
1:60,000 dilution. Both antibodies were diluted in 0.5%
milk-TBS, pH 7.5. The protein bands were visualized
with SuperSignal West Dura enhanced chemilumine-
sence reagent (Pierce; Rockford, IL, USA) and devel-
oped on film.
Statistical analyses
Symbols and/or bar graphs are represented as means ±
standard error of the mean (SEM). Differences
between groups were evaluated using Student’s t-test.
The p values are defined in the figure legends.
Results
In cultured cells, electrogenic transport such as trans-
epithelial Na+ flux can be measured by clamping the
spontaneous potential difference of a confluent, high-
resistance monolayer to zero and recording the SCC. Ion
transport generated by Na+ flux in the reabsorptive
direction can be quantitated with the use of an ENaC-
specific inhibitor, amiloride. Representative ion trans-
port responses of the A6 cell line to maximal and sub-
maximal concentrations of insulin are shown in Fig. 1.
In this cell line, both basal (control) and insulin-stimu-
lated ion flux are predominantly amiloride-sensitive. The
ion transport traces of the M-1 and mpkCCDcl4 cells are
similar to that seen in the A6 cells, except that the M-1
Table 1 Primer sets and probes:
oligonucleotides used for qPCR
analyses
Gene Forward primer Reverse primer Probe
PPARc tgaataaagatggagtcctcatctca ggcttccgcaggtttttga agggccaaggattcatgaccaggg
CD36 cctgcagaaatactagccaacacc tgagtccatgcagtttcc cgaaaacgctggcttctgtatacccga
SGK cggtggactggtggtgtctt agccgtgttccggctataaa ctgtcctgtatgagatgctctacggcctg
Fig. 1 Insulin-stimulated Na+ reabsorption in A6 cells. Confluent
cultures were serum-starved 18–24 h. The solid arrow indicates time
of insulin addition. The open arrow indicates time of amiloride
(105 M) addition. Varying insulin concentrations result in
concomitant rises in net SCC. The magnitude (D SCC) of
reabsorptive Na+ flux stimulated by 30 nM insulin is indicated
by the bracket (SCCt=30 minSCCt=0 min). Symbols represent the
mean of n experiments. The standard error bars were not included
for clarity. Significance of the responses are shown in Fig. 2
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cells display a lower rate of basal ion transport as
compared to the other two cell lines (data not shown).
The dose–response relationships between Na+ flux
and insulin concentrations for all three cell lines are
expressed as the insulin-stimulated increase over baseline
(D SCC) in Fig. 2. Under these experimental conditions,
the rise in SCC elicited by 30 nM insulin is maximal in
all cell lines. The dose–response curves elicited in the
amphibian and mammalian cell lines are virtually iden-
tical. However, in the M-1 cells, the magnitude of the
insulin-stimulated changes in net transport are approx-
imately tenfold less than that observed in either the A6
or mpkCCDcl4 cells (compare the SCC scales between
the panels in Fig. 2). The rate of basal transport ob-
served in the M-1 cell line was also proportionally lower.
Each cell line exhibits a dose-responsive relationship of
insulin-stimulated Na+ transport within normal rodent
plasma insulin concentrations (Table 2).
We performed qPCR on RNA isolated from conflu-
ent M-1 and mpkCCDcl4 cells and measured basal
amounts of PPARc mRNA expression. Both cell lines
express similar amounts of PPARc transcript in the
basal state (Fig. 3a). Concurrently, a band correspond-
ing to PPARc protein was detected in the A6, M-1, and
mpkCCDcl4 cell lines (Fig. 3b). The M-1 cells express a
higher level of PPARc protein as compared to the
mpkCCDcl4 cells.
In order to verify that the agonists used in these
studies were, in fact, functional, PPARc-induced gene
expression was determined using the mpkCCDcl4 cells.
CD36 is a protein commonly upregulated by PPARc in
multiple tissues [25]. Long-term (18–24 h) incubation
with either pioglitazone or GW7845 induced a signifi-
cant increase in CD36 mRNA (Fig. 4a). Concurrently,
CD36 protein abundance was induced upon treatment
with either of the two agonists (Fig. 4b). The effect of
the two agonists on expression of serum and glucocor-
ticoid induced kinase (SGK)—an enzyme that was
previously reported to be upregulated with PPARc
agonist treatment [19]—was also investigated in the
mpkCCDcl4 cells (Fig. 4). We did not observe any
changes in the levels of SGK transcript or protein
expression after a long-term (18–24 h) incubation with
either PPARc agonist.
The majority of basal ion transport in each cell line is
amiloride-sensitive, indicating that it is predominately
due to reabsorptive Na+ movement via ENaC. It is
possible that the PPARc agonists may affect salt and
water homeostasis by modulating basal ENaC activity
rather than by regulating hormonally induced changes in
channel transport. However, differences in the amount
of basal Na+ transport were not observed in either the
A6 or the mpkCCDcl4 cell lines after long-term (18–
24 h) pioglitazone or GW7845 treatment. The effect of
short-term (2 h) agonist incubation was examined in the
mpkCCDcl4 cell line. Neither agonist affected basal Na
+
transport after 2 h (data not shown). On the other hand,
long-term treatment with GW7845 significantly de-
creased basal ion transport compared to the untreated
tissue in the M-1 cell line (Fig. 5). The explanation for
the anomalous GW7845-mediated decrease in basal ion
flux in the M-1 cell line and not the other two cell lines
has not yet been determined.
To ascertain potential insulin-sensitizing effects of the
PPARc agonists, a submaximal (1 nM) insulin concen-
tration was used to stimulate cells preincubated
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Fig. 2 Insulin dose–response curves in principal cell culture
models. (a) A6, (b) M-1, and (c) mpkCCDcl4 cells were serum-
starved 18–24 h and subsequently stimulated with varying concen-
trations of insulin. The magnitude of insulin-stimulated Na+ flux is
depicted in bar graphs representing means ± SEM and are
measured as (DSCC = SCCt=30 minSCCt=0 min) in the case of A6
and mpkCCDc14 cells, and as (DSCC = SCCt=10 minSCCt=0 min)
for the M-1 cells. The number of experiments for each insulin dose
are between 5 and 13, 5 and 14, and 5 and 11 for the A6, M-1, and
mpkCCDcl4 cells, respectively. Statistical significance compared to
the maximal insulin dose (30 nM) is denoted using Student’s t-test;
* p £ 0.05, ** p £ 0.01
Table 2 Rat insulin concentrations
Fasted Nonfasted
Control 0.26 nM [34] 0.36 nM [34]
Fructose-fed
(hyperinsulinemic)
0.71 nM [34] 1.41 nM [34]
Control 0.26 nM [14]
Insulin infusion
(hyperinsulinemic)
0.71 nM [14]
Values represent insulin concentrations in rats during control and
hyperinsulinemic situations.
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(18–24 h) in the presence or absence of either agonist.
Neither pioglitazone nor GW7845 treatment signifi-
cantly increased the amount of Na+ flux elicited by a
submaximal (1 nM) insulin dose in any of the three cell
lines (Fig. 6).
Discussion
Monogenetic aberrations in proteins belonging to the
hormonal axes that regulate ENaC activity have been
shown to cause changes in salt and fluid balance leading
to hypertensive or hypotensive states [9, 31]. Insulin
enhances Na+ reabsorption in the distal tubule and, in
humans, there is a correlation between insulin resistance,
hyperinsulinemia and hypertension that is independent
of age, gender, or degree of obesity [8, 11, 12, 24, 29, 30].
The in vivo studies have been substantiated by work in
cell culture models where it has been conclusively shown
that insulin regulates ENaC activity and cell surface
expression [1, 3, 4].
We focused our study on the potential for direct effects
of PPARc activation in the regulation of salt and water
balance in the principal cells of the distal tubule. Inter-
estingly, like insulin-mediated insertion of GLUT-4
transporters into the plasma membrane of adipose and
skeletal muscle cells [10, 37], insulin-mediated insertion of
ENaC into the apical membrane of principal cells is under
the control of the phosphoinositide (PI) pathway [3, 4,
13]. Therefore, we postulated that PPARc ligands may
have actions not only on cellular glucose uptake but also
on expression and cellular localization of proteins that
regulate other transport processes such as ENaC-medi-
ated Na+ absorption. In addition, PPARc is found in the
distal tubule and it is conceivable that the volume
expansion observed with agonist treatment may be linked
to the natriferic effects of insulin or, alternatively, may be
the result of a direct PPARc effect on Na+ transport.
The significant findings from this investigation
include: (1) net ENaC-mediated Na+ flux in three dis-
tinct in vitro models of the renal principal cell type
exhibit similar dose-dependent regulation by insulin; (2)
the three cell lines express functional PPARc and are,
therefore, capable of modulation by PPARc-activating
agents; and (3) activation of PPARc with either piog-
litazone (a true TZD) or the more potent PPARc ago-
Fig. 3 Basal PPARc expression
levels in M-1 and mpkCCDcl4
cells. (a) The expression of
PPARc mRNA in M-1 and
mpkCCDcl4 cells was
normalized to the expression of
b-actin mRNA and presented
as arbitrary units. (b) PPARc
protein expression in A6, M-1,
and mpkCCDcl4 cells.
Confluent monolayers of each
cell line were lysed, separated
by SDS-PAGE, blotted onto
transfer membrane, and probed
for PPARc. Equal amounts of
protein (100 lg) was loaded in
each lane. The arrow shows an
47 kDa protein
corresponding to PPARc.
Results are representative of
three independent experiments
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nist, GW7845 (a non-TZD), did not change the magni-
tude of (a) basal Na+ transport in two of the cell lines
(A6 and mpkCCDcl4) or (b) insulin-stimulated Na
+
transport in any of the cell lines.
There is a striking similarity between the cell lines
with respect to the insulin dose–response curves for
activation of Na+ transport. These studies represent the
first demonstration of insulin dose–response relation-
ships for the murine cell lines (M-1 and mpkCCDcl4).
The insulin concentration eliciting an approximately
half-maximal response (0.3 nM) in each cell line is
within normal insulin levels for both the fasted and non-
fasted states in rats (compare Table 2 with Fig. 2),
demonstrating that the insulin dose–response relation-
ship in these murine cell lines shows efficacy in the
physiological range. The same is true for the A6 cell line.
The discrepancy between the net magnitude of insulin-
stimulated Na+ flux in the A6, M-1, and mpkCCDcl4
cells remains elusive; but it should be noted that these
differences are not unique to insulin. The magnitude of
the natriferic responses elicited by aldosterone and ADH
vary considerably from one cell line to another but, in
general, follow the same trend observed in the insulin
studies. The explanation may lie in the amount and/or
activity of ENaCs, or, alternatively, may be dictated by
the amount of ENaC regulatory components that each
line expresses.
Previous studies utilizing tissue from dissected neph-
rons have found PPARc expression in various segments
of the distal tubule. In situ hybridization has shown the
expression of PPARc transcripts in human, rabbit, and
rat collecting duct (CD) [17, 19, 36]. Immunohisto-
chemical studies have indicated the presence of the
PPARc protein in freshly isolated rabbit inner medullary
collecting duct (IMDC) and in primary cultures of
IMCD as well as CCDs [17]. Recently, Hong et al. used
immunohistochemical staining to show the expression of
PPARc protein in the distal convoluted tubule, CCDs,
and medullary CDs in human kidney sections. In addi-
tion, this group detected PPARc transcripts in a mouse
IMCD cell line (mIMCD-K2) as well as in M-1 and
human CCD principal cell lines [19].
We detected transcripts for PPARc in the
mpkCCDcl4 and M-1 cells. The A6 cell line was excluded
Fig. 4 Effect of PPARc agonists on CD36 and SGK expression.
Confluent monolayers of mpkCCDcl4 cells were serum-starved
overnight and treated with either vehicle (black bars), 100 nM
GW7845 (white bars), or 10 lM pioglitazone (hashed bars) 18–24 h.
(a) CD36 mRNA or SGK mRNA was normalized to the
expression of b-actin mRNA and presented as arbitrary units.
Bars represent means ± SEM. Statistical significance in gene
expression between PPARc-treated tissues and vehicle-treated
tissues for CD36 mRNA is denoted using Student’s t-test;
* p £ 0.05. Results are representative of two independent experi-
ments. (b) Whole cell lysates of serum-starved mpkCCDcl4 cells
treated 18–24 h with either vehicle (DMSO), pioglitazone (10 lM),
or GW7845 (100 nM) were separated by SDS-PAGE, blotted onto
transfer membrane, and probed for CD36 or SGK. Equal amounts
of protein (100 lg) was loaded in each lane. The open arrow shows
a doublet migrating at 80 kDa corresponding to CD36, whereas
the solid arrow shows a band migrating at 46 kDa corresponding
to SGK. Results are representative of two individual experiments
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from this analysis due to lack of species-specific primers.
The results in the M-1 cell line substantiate the previous
findings of Yang et al., while the results in the
mpkCCDcl4 cell line are novel. Each cell line also ex-
presses PPARc protein in varying amounts. Interest-
ingly, the PPARc protein expression in the M-1 and
mpkCCDcl4 cells does not follow the same trend as the
mRNA expression. This observation may explain the
baseline-lowering effect of GW7845 in the M-1, but not
mpkCCDcl4 cell line (Fig. 3b, c). However, this reason-
ing is not consistent when considering the protein
expression of PPARc in the A6 cells. GW7845 did not
cause a decline in basal transport in this line (Fig. 3a)
even though the A6 cells express the highest amount of
PPARc protein.
We next explored the functionality of the PPARc
agonists used in these studies. qPCR was used to assess
PPARc-induced gene expression in the mpkCCDcl4 cells.
This line was chosen for the gene analyses due to the
availability of species-specific primer sets, as well as the
robust nature of their natriferic responses to insulin.
CD36 is a transmembrane glycoprotein involved in foam
cell formation and this protein has been shown to be
upregulated in response to PPARc treatment [25].
Pioglitazone and GW7845 both caused a significant in-
crease in CD36 mRNA and protein expression, verifying
the functionality of the PPARc agonists.
In summary, PPARc is present in the sections of
the kidney containing principal cells as well as in
cultured principal cell lines. It has been demonstrated
that each cell line utilized in this study also expresses
the protein and/or mRNA for each of the ENaC su-
bunits [2, 23, 26]. Thus, the key components of the
potential PPARc-regulated pathway are expressed in
the cell lines used.
Our studies suggest that the TZDs are not contrib-
uting to the fluid retention through direct regulation of
ENaC or insulin-stimulated ENaC activity. It is possible
that the agonists may be acting on water and Na+
transporting machinery located prior to the distal con-
voluted tubule. Rosiglitazone treatment in Sprague–
Dawley rats was shown to increase protein abundance of
the sodium-hydrogen exchanger-3 (NHE3), the primary
source of Na+ reabsorption in the proximal tubule [32].
However, in the same study, expression of the collecting
duct aquaporins 2 and 3 were shown to be up-regulated
when challenged with rosiglitazone, suggesting that
ADH may have a role in PPARc-mediated fluid reten-
tion and, in agreement with the previously cited papers,
indicate a distal site of action. Also consistent with a
distal effect are the observations of Hong and colleagues,
who showed that treatment of a PPARc-expressing hu-
man CCD cell line with either rosiglitazone (2 lM) or
pioglitazone (20 lM) increased the translocation of
aENaC to the plasma membrane, although the func-
tional ramifications of this observation were not
explored [19].
In the Hong et al. study, the translocation of aE-
NaC was accompanied by an upregulation of SGK
mRNA and activity within 4 h of PPARc agonist
treatment. SGK is a downstream enzyme activated in
the PI pathway—a signaling system shared by various
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Fig. 5 Effect of pioglitazone and GW7845 on basal ion transport.
(a) A6 cells, (b) M-1 cells, and (c) mpkCCDcl4 cells were serum-
starved overnight and treated with either pioglitazone (10 lM) or
GW7845 (100 nM) 18–24 h. Basal transport rates just before
addition of insulin (time=0) in control, pioglitazone, or GW7845
treated cells were compared. Bars depict means ± SEM. The
number of experiments for each condition (control or PPARc-
treated) range between 8 and 13, 4 and 11, and 9 and 11 for A6, M-
1, and mpkCCDcl4 cells, respectively. Statistical significance
compared to the untreated cells is denoted using Student’s t-test;
*p £ 0.05
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ENaC-regulating hormones. In functional studies,
over-expression of wild-type SGK has been shown to
increase basal, but not insulin-stimulated Na+ trans-
port through ENaC [13]. We did not observe PPARc-
induced changes in the amount of SGK transcript or
expressed protein in the mpkCCDcl4 cells. In addition,
neither PPARc agonist induced basal or insulin-stim-
ulated ENaC activity in the same cell line. It is possible
that the PPARc agonists may regulate SGK activity by
a post-translational mechanism. If this is the case, one
would expect PPARc agonist treatment to positively
regulate basal ENaC activity; however in the
mpkCCDcl4 cells, we did not find significant increases
in basal ENaC transport either 2 h (data not shown) or
18–24 h (Fig. 5) after treatment with GW7845
(100 nM) or pioglitazone (10 lM). The differences in
the experimental results between the Hong et al. study
and the present study may be explained by differences
in the cell lines utilized and/or PPARc agonist con-
centrations tested.
On the other hand, SGK has been implicated as both
necessary and rate-limiting for ADH-stimulated Na+
transport [13]. Therefore, it is entirely possible that the
PPARc agonists may be modulating ENaC and/or other
transporter function via other hormonal pathways
independent of insulin.
We have verified that three cell culture models of the
principal cell type respond to physiologically relevant
insulin concentrations in a dose-dependent manner. In
addition, we have shown that PPARc agonists do not
potentiate insulin-mediated Na+ flux in any of the lines,
suggesting that PPARc activation does not regulate fluid
homeostasis via a direct effect on insulin-stimulated
ENaC activity in isolated cell lines. The in vivo situation
may be more complex, encompassing factors that are
not found in cultured cells. These findings are important
in ruling out targets for clinical intervention of the fluid
retention and will provide the basis for future studies
involving the regulation of other renal transporter
functions by PPARc.
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